Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Governance Other
confidence 85%
filed 2026-07-13
Item 1.01
Revelation Biosciences adopted a stockholder rights plan (poison pill) on July 10, 2026, declaring a dividend distribution of one right per outstanding share and filing a Certificate of Designation for Series B Junior Participating Preferred Stock. The rights become exercisable if any person or group acquires 10% or more beneficial ownership without Board approval, entitling other shareholders to purchase shares at a discount as a defensive measure against hostile takeovers.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-13
Item 5.07
This Item 5.07 discloses the results of Chewy's July 9, 2026 annual meeting of stockholders, including voting outcomes on four proposals: election of five Class I directors (Raymond Svider, Marco Castelli, Nat Goldhaber, James Nelson, and Martin H. Nesbitt), ratification of Deloitte & Touche LLP as independent auditor, Say on Pay advisory vote, and frequency of future Say on Pay votes. The detailed vote tallies and Board's recommendation to continue annual Say on Pay votes are material governance disclosures that affect investor understanding of board composition and executive compensation oversight.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-07-13
Item 8.01
Trex entered into a National Distribution Agreement with U.S. Lumber Group (SBP) on July 13, 2026, appointing it as the sole and exclusive national distributor of Trex products in the U.S. and Canada effective January 1, 2027, while simultaneously terminating its entire commercial distribution relationship with Boise Cascade Company effective August 12, 2026. This represents a material realignment of the company's distribution network—a core operational and strategic business decision—rather than a discrete M&A transaction, debt issuance, or other financial event. The news release emphasizes this as a key step toward the company's stated priority to "Optimize our Channels for Growth," and the company is raising full-year 2026 guidance in connection with the announcement, indicating materiality to investors.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 98%
filed 2026-07-13
Item 8.01
Welltower OP LLC issued C$750 million of 3.850% Notes due 2031 and C$400 million of 4.150% Notes due 2033 on July 13, 2026, pursuant to an underwriting agreement. This is a creation of new direct financial obligations totaling C$1.15 billion, with the net proceeds intended for debt repayment and investment in healthcare and seniors housing properties. The disclosure clearly describes the issuance terms, interest rates, maturity dates, and use of proceeds, which are hallmarks of a material debt issuance event.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-13
Item 5.02
Nickolas Stavropoulos was appointed to ONE Gas's Board of Directors on July 13, 2026, expanding the board from eight to nine members. He was assigned to three board committees (Audit, Corporate Governance, and Executive Compensation) and brings 40+ years of energy industry experience, including prior roles as COO of PG&E and National Grid.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-07-13
Item 8.01
Erasca disclosed updated Phase 1 clinical trial data for ERAS-0015 showing encouraging monotherapy responses in KRAS G12X PDAC (57% uORR at RDE), consistent safety profile, and promising combination potential with panitumumab. The company also announced plans to initiate potentially registration-enabling Phase 3 trials in PDAC and NSCLC in 2027. This is a material clinical development milestone for a biotech company's lead candidate that would affect investor assessment of pipeline progress and regulatory pathway, but does not fit the specific categories of earnings release, M&A, impairment, or other defined event types—making it an operational/strategic business event.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 85%
filed 2026-07-13
Item 8.01
The filing discloses the expected issuance of Class A(2026-1) Notes and Class A(2026-2) Notes by Capital One Multi-asset Execution Trust on July 16, 2026. This represents the creation of new direct financial obligations (debt securities), which falls squarely within debt_issuance. The materiality is high given the structured finance context and the explicit disclosure of multiple note classes.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-13
Item 5.02
The Board elected Ms. Ekta Singh-Bushell as a director effective August 1, 2026, and appointed her to the Audit Committee. This is a clear executive appointment to the Board of Directors, the principal disclosed action. While the Item 5.02(d) section also mentions compensatory arrangements (customary non-employee director compensation), the core event is the appointment itself, which is material to investors as it affects board composition and governance.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-07-13
Item 8.01
Kaiser Aluminum's board declared a quarterly cash dividend of $0.77 per share, payable August 14, 2026. This is a routine but material capital allocation decision that affects shareholder returns and reflects the company's financial position and capital management strategy, warranting disclosure under Item 8.01.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-07-13
Item 5.02
Kent P. Hawryluk's departure as Chief Executive Officer and Board member effective July 13, 2026 is the opening and most prominent disclosure in this Item 5.02. While the filing also covers two executive appointments (Hoerter as CEO and Smither as CFO) with compensatory arrangements, the departure of the sitting CEO is the principal event that would materially affect investor assessment of the company's leadership continuity and governance.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-07-13
EX-99.1
Grupo Aeroméxico announced unaudited consolidated financial results for Q2 2026 (ended June 30, 2026), reporting record total revenue of $1.5 billion (12.6% YoY increase), adjusted EBITDAR of $264.2 million with 17.9% margin, and operating income of $67.9 million, along with forward guidance for Q3, Q4, and full-year 2026.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-13
Item 1.01
AFS SENSUB CORP. entered into a definitive agreement to issue approximately $916 million in asset-backed notes across multiple classes (Class A-1 through Class C) through a newly formed issuing entity, with closing scheduled for July 15, 2026. The transaction includes an underwriting agreement dated July 9, 2026, and specifies principal amounts, interest rates, and the underwriter syndicate.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 96%
filed 2026-07-13
Item 1.01
Talos Energy issued $800 million in aggregate principal amount of 8.000% Second-Priority Senior Secured Notes due 2034 under an indenture dated July 13, 2026. The proceeds are designated for the Gulf of America Acquisition, redemption of existing 9.000% Notes, and general corporate purposes, representing a material refinancing and capital-raising event.
View raw filing on EDGAR →
6-K
Earnings release
confidence 75%
filed 2026-07-13
EX-99.1
This is a clinical update press release announcing mature overall survival data from the INSIGHT-003 Phase I trial (mOS 30.9 months in 1L NSCLC) and a root cause analysis update for the discontinued TACTI-004 Phase III trial. While not a traditional earnings release of financial results, it discloses material clinical trial outcomes for the company's lead candidate eftilagimod alfa that would significantly affect investor assessment of the drug's development prospects and commercial potential. The positive INSIGHT-003 data and the investigation into TACTI-004's failure represent key clinical milestones material to the registrant's pipeline and strategy.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-13
Item 3.02
TOP Financial Group completed a private placement on July 9, 2026, issuing 214,431,222 Class A ordinary shares and warrants to purchase 428,862,444 additional shares to non-U.S. investors under Regulation S, raising $80 million in gross proceeds. This substantially dilutive issuance increased outstanding Class A shares from 27.1 million to 247.9 million, materially affecting existing shareholders' ownership percentages and the company's capital structure.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 92%
filed 2026-07-13
The 6-K discloses one-time special discretionary bonus awards to two directors (Mr. Lee Seng Chi, chairman and CEO, and Mr. Thien Chiet Chai, director) satisfied by issuance of Class B shares totaling 50,000 shares valued at US$100,000. This is a compensatory arrangement for named executives and constitutes a material disclosure of equity compensation that would affect a reasonable investor's assessment of executive remuneration and potential dilution.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-07-13
Item 7.01
The disclosure centers on the pending separation of ADI Global Distribution Inc. from Resideo Technologies, Inc., with completion expected August 3, 2026, and ADI trading to commence August 4, 2026. This constitutes a material change of control and restructuring event. While Item 7.01 is used for the investor day announcement, the substance is a major M&A activity—the spin-off of a significant business segment—which materially affects the registrant's structure and shareholder value.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-13
EX-99.1
This exhibit is a press release announcing positive clinical study results for CYTOGAM presented at the 2026 ISHLT Annual Meeting. The disclosure highlights investigator-initiated research demonstrating improved clinical outcomes in CMV high-risk lung transplant recipients receiving CMVIG prophylaxis, with mechanistic insights into immune modulation. While the results support increased product utilization and are strategically important to Kamada's commercial portfolio, this is not a discrete earnings release (no financial results disclosed), nor does it fit other specific event categories. It represents a material operational/commercial milestone—positive clinical validation of a marketed product—that would affect investor assessment of the product's market potential and the company's growth strategy.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-13
EX-99.1
The press release announces FDA grant of Regenerative Medicine Advanced Therapy (RMAT) designation for Allocetra™ in age-related knee osteoarthritis. This is a material regulatory milestone that accelerates clinical development and provides a pathway to expedited approval, representing a significant operational and strategic advancement for the company's lead therapeutic program. While not fitting a discrete named event type, this regulatory designation is clearly operational/strategic in nature and material to investors assessing the company's development trajectory and commercial prospects.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-13
EX-99.1
This press release announces a multi-year strategic partnership between Marti and Tensor to deploy autonomous vehicles on Marti's mobility platform across Turkish cities. The disclosure describes a material operational and strategic business development—a significant partnership involving fleet deployment of new technology—that does not fit a specific named event type. While it involves a material contract and strategic initiative, it is neither an M&A transaction, a discrete financial event, nor a governance matter; it is a material operational partnership that would affect a reasonable investor's assessment of the company's growth strategy and competitive positioning.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-07-13
EX-99.1
The press release announces that POMDOCTOR has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share under Listing Rule 5450(a)(1), resolving a prior non-compliance notice issued on January 29, 2026. While the announcement is positive (compliance restored), the underlying event—a delisting risk triggered by failure to maintain minimum bid price—is material to investors. The disclosure directly addresses a continued listing rule and the threat of delisting that preceded it, making this a delisting_risk classification focused on the resolution of that material threat.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-07-13
EX-99.1
This press release announces a 1-for-10 share consolidation approved by shareholders on March 4, 2026, and implemented by the Board on June 30, 2026, effective July 13, 2026. The consolidation is a governance/capital structure action taken to maintain Nasdaq compliance with the minimum bid price rule of $1.00 per share. While it affects share structure and is material to investors' understanding of the company's capitalization, it is a governance event rather than a discrete operational, financial, or legal event, and does not fit the specific categories of exec appointment/departure, compensation, M&A, or other named types.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-13
Item 8.01
This Item 8.01 discloses pro forma financial statements reflecting the impact of an Asset Purchase Agreement entered into on April 7, 2026, between Plum III Merger Corp., Sierra Blanca Quarry LLC, and Tactical Resources Corp. The filing explicitly references "the previously announced business combination among Plum, Tactical and PubCo" and presents unaudited pro forma balance sheet and income statement as of April 30, 2026 to illustrate the transaction's financial impact. This constitutes material M&A activity—specifically a business combination/merger transaction—even though the pro forma statements are furnished for illustrative purposes only and the transaction had not yet closed as of the filing date.
View raw filing on EDGAR →
6-K
Cybersecurity Incident
confidence 85%
filed 2026-07-13
EX-99.1
The press release discloses a material disruption to subsidiary NetNut Ltd.'s proxy network operations of unknown root cause, with the Company appointing external cybersecurity and forensic experts to investigate whether third parties misused the network or technical issues affected operations. This constitutes a material cybersecurity incident requiring disclosure under Item 1.05. The Company is also implementing workforce reductions affecting approximately one-third of employees and suspending service operations pending investigation and compliance review, indicating material operational impact from the incident.
View raw filing on EDGAR →
8-K
Exec departure
confidence 92%
filed 2026-07-13
Miles Everson, a director designee of Toby Neugebauer, resigned from the Board of Directors of Fermi Inc. effective immediately on July 10, 2026. The resignation was prompted by disagreement over access to books and records and the Board's delegation of financing oversight to the Finance Committee. This is a clear director departure under Item 5.02, and is material because it involves a board-level departure with stated governance disagreements.
View raw filing on EDGAR →
6-K
M&A activity
confidence 98%
filed 2026-07-13
EX-99.1
Greenfire Resources entered into a definitive agreement to acquire all issued and outstanding shares of Connacher Oil and Gas Limited for approximately C$1.277 billion in cash, with closing expected in August 2026. The acquisition is expected to increase pro forma production from ~14,500 to ~34,000 Bbl/d and generate identified synergies of ~$30 million annually.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-07-13
EX-99.2
Greenfire Resources announced a rights offering of common shares for gross proceeds of at least $575 million at a subscription price not to exceed $6.74 per share (15% discount to VWAP), to be conducted on an unregistered basis pending prospectus filing. The offering is tied to financing the Connacher Oil acquisition.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-13
The 6-K discloses entry into securities purchase agreements on July 2, 2026, whereby Mint Incorporation Limited issued 4,310,350 Class A ordinary shares to new and existing investors at US$0.464 per share (20% discount to market) for aggregate proceeds of US$2,000,000. This is a classic private placement (PIPE) of unregistered equity securities relying on Section 4(a)(2) and Regulation S exemptions, materially dilutive to existing shareholders and a significant capital raise for the company.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 95%
filed 2026-07-13
The 6-K furnishes an Underwriting Agreement dated July 6, 2026, and a Fourth Supplemental Indenture dated July 13, 2026, evidencing issuance of subordinated debt by Canadian Imperial Bank of Commerce. The exhibit index lists counsel opinions and tax opinions supporting the debt offering, and the filing is signed by the Vice-President of Global Term Funding, Treasury. This is a material creation of a direct financial obligation through debt issuance.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 95%
filed 2026-07-13
EX-99.1
This exhibit is Polyrizon's Compensation Policy for Executive Officers and Directors, adopted on July 13, 2026, pursuant to Israeli Companies Law requirements. It comprehensively sets forth compensation instruments (base salary, benefits, cash bonuses, equity awards, change-of-control provisions, and termination terms), performance objectives, bonus formulas, equity vesting requirements, and clawback provisions. The policy governs compensation arrangements approved after its adoption date and applies for three years unless amended. This is a material disclosure of compensatory arrangements for executive officers and directors that would affect a reasonable investor's assessment of the company's governance and executive incentive structure.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-13
EX-99.1
This press release discloses positive early insights from an ongoing Phase I/IIa first-in-human clinical trial (CMND-100) for alcohol use disorder, highlighting favorable safety profile, successful recruitment, and non-hallucinogenic differentiation. While the disclosure is operational in nature (clinical trial progress), it does not fit the specific event categories of earnings_release, exec_appointment/departure, or material_litigation. The material clinical trial progress and positive investigator feedback from leading institutions (Yale, Johns Hopkins) would affect a reasonable investor's assessment of the company's pipeline and development trajectory, warranting materiality classification.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 85%
filed 2026-07-13
Item 2.03
MSP Recovery entered into a letter agreement with VRM on July 8, 2026, receiving a $0.3 million advance to support operating expenses, creating a new direct financial obligation. The amendments to the Master Transaction Agreement and Security Agreement materially restructured the Company's financing arrangements, including removal of Operating Reserve and Reserve Account from excluded collateral, expanding VRM's security interests.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-13
Item 3.01
Pluri Inc. received a written notice from Nasdaq on July 7, 2026, indicating non-compliance with Listing Rule 5550(b)(2), which requires a minimum market value of listed securities (MVLS) of $35 million. The company has been given 180 calendar days until January 4, 2027, to regain compliance, with the explicit warning that failure to do so will result in delisting notification. This is a classic delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the company's continued listing status.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-13
Item 1.01
Singularity Future Technology completed a private placement of 5,263,158 shares of common stock and 15,789,474 warrants to non-U.S. persons under Regulation S for approximately $2,000,000, closing on July 13, 2026. This unregistered equity issuance materially dilutes existing shareholders and signals capital-raising activity.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-13
Item 8.01
RMG ML Sports Holdings announced the commencement of separate trading of its Class A ordinary shares and rights, previously bundled in units, effective July 17, 2026. This is a routine capital structure event for a SPAC following its IPO (completed June 11, 2026), where unit holders are given the option to separate their securities into component parts for independent trading. While material to investors holding the units, this is an operational/administrative milestone rather than a governance, financial, legal, or existential event—it does not fit the specific categories of earnings, executive changes, M&A, impairment, litigation, or debt activity.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-07-13
Autodesk established an unsecured commercial paper program on July 13, 2026, with a maximum aggregate face amount of $2.0 billion. The company explicitly states it expects to use proceeds to partially finance a previously announced merger transaction (MaintainX acquisition). This constitutes creation of a new direct financial obligation and financing arrangement, fitting the debt_issuance category. The materiality is high given the $2 billion program size and its stated use for M&A financing.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-07-13
The 6-K discloses a registered direct offering completed on July 13, 2026, in which Haoxi issued 300,000 Class A ordinary shares at $0.40 per share and 9,700,000 pre-funded warrants (exercisable at $0.33) for gross proceeds of $4,000,000. This is a dilutive equity issuance that raises capital through the sale of registered securities, materially affecting share count and ownership structure. The disclosure explicitly states that 5,100,000 Class A shares were issued as of July 13, 2026, including shares from warrant exercises, representing a significant dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 85%
filed 2026-07-13
Item 7.01
The filing discloses REFI's completion of a financing transaction involving the issuance of approximately $62.5 million in second-lien notes by Koach Properties Manager LLC to REFI in exchange for 4,306,754 common shares valued at $14.53 per share. The notes bear a 10.0% cash interest rate plus 2.0% PIK interest and have a weighted average time to maturity of approximately 12 years. This represents a material creation of a direct financial obligation for REFI, fitting the debt_issuance category. The dilutive share issuance is secondary to the primary event of acquiring the debt instrument.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-07-13
Item 8.01
This disclosure announces the implementation of a 1-for-10 reverse stock split approved by stockholders via written consent on December 1, 2025, with an effective date of July 24, 2026. While a reverse stock split is a capital structure event with operational consequences (trading symbol, CUSIP change, share consolidation), it is fundamentally a governance matter involving stockholder approval and charter amendment. The event is material to investors as it affects share count, trading mechanics, and potential delisting-risk implications, but does not fit the specific categories of exec_appointment, exec_departure, exec_compensation, shareholder_vote_results (which typically refers to voting outcomes on substantive matters), or delisting_risk (which would require an actual delisting notice). Governance_other is the most appropriate classification.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-07-13
Item 1.01
The Sponsor deposited $229,700 into the trust account and entered into a convertible promissory note (Second Extension Note) to extend the Company's deadline to consummate a Business Combination from June 22 to July 22, 2026, directly affecting the SPAC's ability to complete its material acquisition.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-07-13
Item 8.01
The Company mailed proxy materials for an Annual Meeting of Stockholders to vote on multiple governance matters including extension of the business combination deadline, amendment of the Investment Management Trust Agreement, election of five board members, ratification of auditor appointment, and meeting adjournment authority.
View raw filing on EDGAR →
6-K
Exec Compensation
confidence 85%
filed 2026-07-13
EX-99.1
This announcement updates the grant of RSUs (Restricted Stock Units) under the 2021 and 2022 RSU Schemes and options under the Post IPO Share Option Scheme. The disclosure concerns equity compensation awards to executives and employees, which falls squarely within executive compensation. The material correction of the AGM date (May 19, 2025 vs. May 20, 2026) clarifies the authorization basis for these equity grants, making this a material disclosure affecting investor understanding of executive incentive arrangements.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-13
Item 3.01
Nasdaq issued a press release on July 10, 2026 stating that Actelis Networks' common stock, suspended from trading on April 10, 2026, would be officially delisted from Nasdaq. The company's stock has transferred to the OTCQB Venture Market. This is a material delisting event that directly affects the registrant's listing status and investor access to the security.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-13
Item 7.01
Tavia Acquisition Corp. and Vita Inclinata Technologies announced entry into a non-binding letter of intent for a proposed business combination (de-SPAC transaction) that would result in Vita becoming publicly traded. The transaction values Vita at a pre-money enterprise value of $450 million. Although the LOI is non-binding and subject to definitive agreement execution, this represents a material M&A activity disclosure under Item 1.01 principles—the announcement of a proposed merger or business combination that would materially affect the registrant.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-07-13
Item 1.01
Launch One Acquisition Corp. entered into Non-Redemption Agreements with shareholders to extend its Business Combination Period from July 15, 2026 to January 15, 2027, securing shareholder support and trust account funds necessary for pursuing a future business combination.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-13
Item 5.07
Shareholders approved the Extension Amendment Proposal to extend the Business Combination deadline to January 15, 2027 (19,852,479 votes for, 5,967,148 against) and ratified WithumSmith+Brown, PC as independent auditor (21,388,209 votes for, 4,023,889 against); 21,226,389 Public Shares were redeemed in connection with the meeting.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-07-13
Item 3.03
T3 Defense implemented a 1-for-50 reverse stock split to "raise the per share bid price of the Company's Common Stock above $1.00 per share and bring the Company back into compliance with Nasdaq Listing Rule 5550(a)(2)." This is a direct response to a delisting risk triggered by the stock trading below the $1.00 minimum bid price requirement. The filing explicitly states the company was out of compliance and needed to regain it, making this a material delisting-risk disclosure.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-07-13
The filing discloses a material acquisition: SoundHound AI's merger with LivePerson, Inc., pursuant to an Amended and Restated Merger Agreement dated July 2, 2026. The 8-K provides unaudited pro forma condensed combined financial information showing the combined entity's balance sheet and statements of operations, reflecting total consideration of approximately $304 million in stock and cash. This is a material change of control transaction that would significantly affect investor assessment of the registrant.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-13
Item 5.07
Amesite Inc. held its annual meeting on July 13, 2026, with shareholders approving four proposals: election of Class II directors (Sastry and Brewer), ratification of Novogradac & Company LLP as independent auditor, amendment to the 2018 Equity Incentive Plan increasing available shares by 1,000,000 for general issuance and 1,000,000 for incentive stock options, and approval of warrant exercise issuances totaling 2,787,464 shares.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-07-13
The 6-K discloses multiple governance events: (1) appointment of Erez Simha as Chairman on July 9, 2026; (2) appointment of Rafia Abdulla Mohamed Saeed AlMulla as an independent director on July 7, 2026; (3) constitution of Board committees with specified chair and member assignments; and (4) change of independent auditor from Reliant CPA PC to CBIZ CPAs effective July 9, 2026. While the filing contains both an exec_appointment (director and chairman appointments) and an auditor_change, the body of the report bundles these as a single governance disclosure package. Since the filing presents these as a coordinated governance restructuring rather than discrete events, and no single event dominates, governance_other best captures the composite nature of the disclosure.
View raw filing on EDGAR →